Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase NA 2Phase EARLY_PHASE1 1

Status

Withdrawn 2Terminated 2Unknown 1

Sponsor Class

OTHER 5INDUSTRY 1

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 4Tumor-Agnostic 1

Conditions

Pancreatic Neoplasms 3Adenocarcinoma 2Pancreatic Ductal Adenocarcinoma 1Neoplasms 1

Interventions

Cisplatin 1041Cyclophosphamide 973Carboplatin 954Radiotherapy 893Bevacizumab 847Gemcitabine 817pembrolizumab 759Paclitaxel 738Docetaxel 734Oxaliplatin 706Capecitabine 648Fluorouracil 564Rituximab 559Nivolumab 506Dexamethasone 487Etoposide 468Doxorubicin 458Irinotecan 442Drug Therapy 402Leucovorin 377Cytarabine 342Cetuximab 340Lenalidomide 326Trastuzumab 323Pemetrexed 315durvalumab 295Filgrastim 287Magnetic Resonance Spectroscopy 278Temozolomide 275Prednisone 273

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 2 × OTHER × PEGPH20 × Clear all
NCT04058964 2020-03-13

Pembrolizumab and PEGPH20 in Treating Patients With Metastatic Pancreatic Cancer

M.D. Anderson Cancer Center

Phase 2 Withdrawn
Gastrointestinal

Pancreatic Neoplasms

NCT04134468 2020-01-31

MRI Effects of Pegvorhyaluronidase Alfa (PEGPH20) in Pancreatic Ductal Adenocarcinoma

Abramson Cancer Center at Penn Medicine

Phase 2 Withdrawn
Gastrointestinal

Pancreatic Ductal Adenocarcinoma

NCT02487277 2020-01-02

PEGPH20, Gemicitabine and Nab-Paclitaxel for Pancreatic Ductal Adenocarcinoma

University of California, San Francisco

Phase 2 Terminated
3 enrolled 8 charts
Tumor-Agnostic

Adenocarcinoma

NCT03634332 2019-05-07

Second-line Study of PEGPH20 and Pembro for HA High Metastatic PDAC

Pancreatic Cancer Research Team

Phase 2 Unknown
35 enrolled
Gastrointestinal

Adenocarcinoma, Neoplasms, Pancreatic Neoplasms

NCT02910882 2019-04-11

HALO-IST

Scripps Health

Phase 2 Terminated
4 enrolled
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡